SynthesisCurrent pain and headache reports2026
The Efficacy and Safety of Rimegepant Every Other Day as Preventive Treatment for Migraine: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Synthesis in Current pain and headache reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRimegepant is an oral CGRP receptor antagonist initially approved for the acute treatment of migraine, demonstrating rapid onset of action and a favorable tolerability profile. Recently, a limited number of randomized controlled trials have evaluated its prophylactic use. The aim of this systematic review and meta-analysis is to assess the effectiveness and safety of rimegepant as a preventive therapy for migraine. METHODOLOGY: This systematic review and meta-analysis followed PRISMA guidelines and was registered in PROSPERO (ID: CRD420251142208). We systematically searched Embase, PubMed, Scopus, Cochrane Central Register of Controlled Trials, Science Direct, and Clinical trials.gov from inception to March 2026. Keywords and MeSH terms were applied to identify randomized controlled trials assessing rimegepant for migraine prevention compared with placebo. Primary efficacy endpoints were the change from the observation period in the mean number of monthly migraine days over the entire study period ( Weeks 1–12 ), in the last month (Weeks 9–12 ), and in the first month (Weeks 1–4 ) Additional primary outcomes include the change from baseline in MSQ scores, the proportion of participants achieving ≥ 50% reduction in moderate to severe migraine attacks from the observation phase, and the reported safety outcomes.
resultsScreening of 792 articles yielded four randomized controlled trials comprising 2,365 participants. Rimegepant significantly reduced monthly migraine days compared with placebo : in the first four weeks (MD − 1.49; 95% CI: −1.84 to − 1.15, p < 0.00001; I²=31%), over the entire study period (MD − 0.98; 95% CI: − 1.33 to − 0.64, p < 0.00001; I²=43%), and in the last four weeks (MD − 0.91; 95% CI: −1.39 to − 0.44, p < 0.00001; I²=47%). Migraine Specific Quality-of-life score was improved (MD 4.36; 95% CI: 2.80 to 5.92, p < 0.00001; I²=9%). Responders rate of ≥ 50% reduction in the number of moderate-to-severe migraine attacks : in the last four weeks was higher in rimegepant group (RR 1.19; 95% CI: 1.04 to 1.36, p = 0.010;I²=0) and over the entire study period (RR 1.72; 95% CI: 0.86 to 3.34, p = 0.12;I²=92). Adverse events leading to discontinuation were higher in rimegepant (RR 1.76; 95% CI: 0.90 to 3.46, p = 0.10; I²=0). Rimegepant was associated with higher rates of nausea (RR 2.02; 95% CI: 1.02 to 4.00, p = 0.05; I²=0).
conclusionTo our knowledge, this is the first systematic review and meta-analysis evaluating rimegepant for migraine prophylaxis. Rimegepant showed statistically significant pooled effect in reducing monthly migraine days and was associated with improved quality of life. However, further studies are warranted to prove the clinical effectiveness of rimegepant as preventive treatment for migraine.
Indexed as
Identifiers
42024209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.